D.C. Circuit Rejects Medical Product Company’s Challenge to Rescinded CMS Policy
- February 23, 2024
A lawsuit brought by a manufacturer of medical products containing human cells, tissues, or cellular or tissue-based products (HCT/P) was largely moot because the Centers for Medicare & Medicaid Services (CMS) had rescinded an automatic-denial reimbursement policy that was briefly in place, the D.C. Circuit held February 16.
ARTICLE TAGS
You must be logged in to access this content.